Edition:
United States

INSYS Therapeutics Inc (INSY.O)

INSY.O on Consolidated Issue listed on NASDAQ Global Market

7.83USD
20 Jul 2018
Change (% chg)

$-0.46 (-5.55%)
Prev Close
$8.29
Open
$8.31
Day's High
$8.36
Day's Low
$7.65
Volume
754,559
Avg. Vol
635,490
52-wk High
$14.00
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $611.88
Shares Outstanding(Mil.): 73.81
Dividend: --
Yield (%): --

Financials

  INSY.O Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -3.23 -- --
ROI: -141.24 -3.65 13.18
ROE: -148.73 -5.62 15.09

U.S. judge questions scope of indictment against Insys founder

BOSTON A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal.

Jul 17 2018

U.S. judge questions scope of indictment against Insys founder

BOSTON, July 17 A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal.

Jul 17 2018

Florida doctor admits taking kickbacks from Insys, others

June 4 A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.

Jun 04 2018

Minnesota sues opioid maker Insys over improper drug marketing

Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc , accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

May 30 2018

UPDATE 3-Minnesota sues opioid maker Insys over improper drug marketing

May 30 Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

May 30 2018

Minnesota sues opioid manufacturer Insys over drug marketing

May 30 The state of Minnesota on Wednesday sued Insys Therapeutics Inc, accusing the pharmaceutical manufacturer of illegally marketing a powerful fentanyl-based pain medicine intended for cancer patients for other uses.

May 30 2018

BRIEF-Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam Complaints

* INSYS THERAPEUTICS RESPONDS TO UNSEALING OF PREVIOUSLY FILED QUI TAM COMPLAINTS AND RECAPS TRANSFORMATION EFFORTS

May 15 2018

U.S. joins whistleblower case against Insys over kickbacks

The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications.

May 14 2018

U.S. joins lawsuits against opioid maker Insys over kickback scheme

May 14 The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit.

May 14 2018

BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East

* INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST

May 08 2018

Earnings vs. Estimates